Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Weight control issues: perspectives in aesthetic medicine
https://doi.org/10.33667/2078-5631-2024-25-8-12
Abstract
Over the past 30 years, the number of people with obesity has almost doubled in the world – a chronic disease accompanied by progressive metabolic disorders and an increased risk of developing diseases such as diabetes, hypertension, coronary heart disease, etc. The rapidly growing number of overweight adults and adolescents, the severity and low efficiency of existing traditional methods of treating obesity, prompt the search for the most effective and safe methods of therapy. Semaglutide is a glucan-like peptide 1 agonist that has demonstrated promising efficacy not only in glycemic control, but also in weight loss by delaying gastric emptying, enhancing and prolonging the feeling of satiety, reducing appetite and energy consumption. The article discusses the main mechanisms of action of semaglutide, and also presents data from STEP studies on the efficacy and safety of semaglutide at a dose of 2.4 mg per week in patients with obesity or overweight without diabetes mellitus.
About the Authors
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Russian Federation
Larisa S. Kruglova - DM Sci (habil.), professor, head of Dept of Dermatovenereology and Cosmetology.
Moscow
A. V. Tamrazova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Russian Federation
Anait V. Tamrazova - postgraduate student of Dept of Dermatovenereology and Cosmetology.
Moscow
References
1. Dedov I. I., Melnichenko G. A., Shestakova M. V., et al. National clinical guidelines for the treatment of morbid obesity in adults. 3rd revision (treatment of morbid obesity in adults). Obesity and Metabolism. 2018; 15 (1): 53–70. (In Russ.). https://doi.org/10.14341/omet2018153–70
2. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9(1). doi: 10.1186/1471-2458-9-88
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050. doi:10.1016/S0140–6736(23)02750-2
4. Hall KD, Ayuketah A, Brychta R, et al. Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab. 2019;30(1):67–77.e3. doi:10.1016/j.cmet.2019.05.008
5. Dollman J, Norton K, Norton L. Evidence for secular trends in children’s physical activity behaviour. Br J Sports Med. 2005;39(12):892–897. doi:10.1136/bjsm.2004.016675
6. Ryan, DH, and Sarah Ryan Yockey. “Weight Loss and Improvement in Comorbidity: Differences at 5 %, 10 %, 15 %, and Over.” Current obesity reports vol. 6,2 (2017): 187–194. doi:10.1007/s13679–017–0262-y
7. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831
8. Aggarwal, Rahul et al. “Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States.” Progress in cardiovascular diseases vol. 68 (2021): 97–98. doi:10.1016/j.pcad.2021.09.007
9. Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023;33(3):159–166. doi:10.1016/j.tcm.2021.12.008
10. Chrysi К., Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes therapy: research, treatment and education of diabetes and related disorders vol. 2,2 (2011): 101–21. doi:10.1007/s13300-011-0002-3
11. Ard J, Fitch A, Fruh S, Herman L. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Adv Ther. 2021;38(6):2821–2839. doi:10.1007/s12325-021-01710-0
12. Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol. 2012;166(1):27–41. doi:10.1111/j.1476–5381.2011.01687.x
13. Vilsbøll T., et al. “Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.” The Journal of clinical endocrinology and metabolism vol. 88,1 (2003): 220–4. doi:10.1210/jc.2002–021053
14. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726
15. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 20142021. [Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.]
16. Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug Des Devel Ther. 2024;18:2555–2570. Published 2024 Jun 25. doi:10.2147/DDDT.S470826
17. Shabutdinova O. R., Dautov A. R., Samkov A. A. et al. Semaglutide: efficacy in weight loss and side effects when used according to the SUSTAIN, PIONEER, STEP studies. Problems of Endocrinology. 2023;69(3):68–82. (In Russ.). https://doi.org/10.14341/probl13197
18. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725
19. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis [published correction appears in JAMA. 2016 Sep 6;316(9):995. doi: 10.1001/ jama.2016.11657]. JAMA. 2016;315(22):2424–2434. doi:10.1001/jama.2016.7602
20. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083–2091. doi:10.1038/s41591-022-02026-4
21. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224
22. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221–32. DOI: 10.1056/NEJMoa2307563
23. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984. doi:10.1016/S 0140–6736(21)00213-0
24. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
25. Ruder K. As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging. JAMA. 2023;330(22):2140–2142. doi:10.1001/jama.2023.16620
26. Sun K., Kusminski C. M., Scherer P. E. Adipose tissue remodeling and obesity // J. Clin. Invest. 2011. Vol. 121, N 6. P. 2094–101. DOI: https://doi.org/10.1172/JCI45887 PMID: 21633177; PMCID: PMC 3104761
27. Gkogkolou Р., Böhm М. Advanced glycation endproducts, Dermato-Endocrinology.-2012.– 4:3, 259–270, DOI: 10.4161/derm.22028
28. Garcia-Hidalgo L., Orozco-Topete R., Gonzalez-Barranco J., Villa A. R., Dalman J. J., Ortiz-Pedroza G. Dermatoses in 156 obese adults // Obes. Res. 1999. Vol. 7, N 3. P. 299–302. DOI: https://doi.org/10.1002/j.1550–8528.1999.tb00410.x PMID: 10348502
29. Nemchaninova O. B., Dolgikh M. Yu. Structure of dermatological pathology in children and adolescents with overweight and obesity // Journal of Siberian Medical Sciences. 2019. No. 2. P. 61–70. (In Russ.). DOI: https://doi.org/10.31549/2542-1174-2019-2-61-70
Review
For citations:
Kruglova L.S., Tamrazova A.V. Weight control issues: perspectives in aesthetic medicine. Medical alphabet. 2024;(25):8-12. (In Russ.) https://doi.org/10.33667/2078-5631-2024-25-8-12
Views:
104
Email this article 